Literature DB >> 10761789

Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?

P Shen1, J M Guenther, L A Wanek, D L Morton.   

Abstract

BACKGROUND: Although more than 90% of the morbidity and mortality from localized cutaneous melanoma occurs in the first decade after initial surgical treatment, melanoma can recur after a 10-year disease-free interval (DFI) with fatal consequences. We reviewed our melanoma data base of more than 8,500 prospectively acquired patients to identify clinicopathological factors that affect the type, rate of occurrence, and outcome of disease recurring 10 years or more after surgical treatment of primary cutaneous melanoma.
METHODS: From 1971 to 1997, 1907 melanoma patients treated at our cancer center reached or presented with a DFI of 10 years or more after surgical treatment of clinically localized melanoma. Of these, 217 (11%) patients had recurrences (mean DFI, 182 months). The sites of recurrence were local/in-transit in 26 (12%) patients, regional lymph nodes in 101 (47%) patients, and distant sites in 90 (41%) patients.
RESULTS: Univariate and multivariate analysis, using patient age and sex, type of initial treatment, and the site, Breslow thickness, and Clark level of the initial tumor, showed that the type of treatment for the primary tumor was a significant (P = .0005) prognostic factor in the development of late nodal recurrence. Of the 217 patients who had recurrences, 172 (79%) had undergone wide local excision for their primary melanoma, and 45 (21%) had undergone wide local excision plus elective lymph node dissection (ELND). The rates of nodal recurrence were 53% (92 of 172) and 20% (9 of 45), respectively, a significant (P = .0001) difference. When all patients with a DFI of 10 years or more were stratified by type of initial treatment, the ELND group demonstrated a significant improvement in disease-free survival and overall survival.
CONCLUSIONS: The risk of late-recurring nodal disease increases and the chance of long-term survival decreases when wide local excision is performed without ELND. With the advent of sentinel lymphadenectomy, ELND can be selectively performed only for those nodal basins with occult tumor cells, thereby decreasing operative morbidity but allowing identification and early removal of nodal micrometastases.

Entities:  

Mesh:

Year:  2000        PMID: 10761789     DOI: 10.1007/s10434-000-0114-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.

Authors:  A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman
Journal:  Br J Dermatol       Date:  2012-11-15       Impact factor: 9.302

3.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

4.  Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.

Authors:  Donald L Morton; Dave S B Hoon; Alistair J Cochran; Roderick R Turner; Richard Essner; Hiroya Takeuchi; Leslie A Wanek; Edwin Glass; Leland J Foshag; Eddy C Hsueh; Anton J Bilchik; David Elashoff; Robert Elashoff
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

5.  Late recurrence in melanoma: clinical implications of lost dormancy.

Authors:  Mark B Faries; Shawn Steen; Xing Ye; Myung Sim; Donald L Morton
Journal:  J Am Coll Surg       Date:  2013-05-03       Impact factor: 6.113

6.  Construction of a Diagnostic Model for Lymph Node Metastasis of the Papillary Thyroid Carcinoma Using Preoperative Ultrasound Features and Imaging Omics.

Authors:  Chao Zhang; Lihua Cheng; Weiwen Zhu; Jian Zhuang; Tong Zhao; Xiaoqin Li; Wenfeng Wang
Journal:  J Healthc Eng       Date:  2022-02-08       Impact factor: 2.682

7.  The Antitumor Activity of Antrodia camphorata in Melanoma Cells: Modulation of Wnt/β-Catenin Signaling Pathways.

Authors:  You-Cheng Hseu; Hsiao-Tung Tsou; K J Senthil Kumar; Kai-Yuan Lin; Hsueh-Wei Chang; Hsin-Ling Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-25       Impact factor: 2.629

8.  Local recurrence and distant metastases 18 years after resection of the greater omentum hemangiopericytoma.

Authors:  Maciej Slupski; Ilona Piotrowiak; Zbigniew Wlodarczyk
Journal:  World J Surg Oncol       Date:  2007-06-06       Impact factor: 2.754

9.  Decoding melanoma metastasis.

Authors:  William E Damsky; Lara E Rosenbaum; Marcus Bosenberg
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

10.  Late Metastatic Melanoma after 25 Years: A Case Report and a Brief Literature Review.

Authors:  Elena Pescarini; Gabriela Spanikova; Zacharia Mbaidjol; Eleonora De Antoni; Vincenzo Vindigni; Franco Bassetto
Journal:  Case Rep Surg       Date:  2020-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.